<!doctype html>
<html class="no-js" lang="en">
  <head>
    <meta charset="utf-8">
		<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=0, minimum-scale=1.0, maximum-scale=1.0">
    <meta name="format-detection" content="telephone=no">
		<title>Adverse Reactions</title>
    <link rel="stylesheet" href="../shared/css/foundation.css" type="text/css">
    <link rel="stylesheet" href="../shared/css/global.css" type="text/css">
    <link rel="stylesheet" href="css/slide.css" type="text/css">
    <script type="text/javascript" src="../shared/js/vendor/modernizr.js"></script>
  </head>
  <body id="D05" class="subpage" data-trace="trace_d05-mono_landing.jpg" data-overlay-trace="trace_d05-adj_landing-chart_overlay.jpg">
    <main class="slide">
      <div class="row collapse">
        <section class="columns">
          <nav id="header-nav" class="row"></nav>
          <article class="row landscape">
            <h2 class="left">Adverse Reactions</h2>
            <ul class="tabs" data-tab>
              <li class="tab-title active">
                <a href="#adj_tab" aria-selected="true">Adjunctive <br>Therapy</a>
              <li class="tab-title">
                <a href="#mono_tab">Monotherapy</a>
              </li>
              <li class="tab-title">
                <a href="#hypnatremia_tab">Hyponatremia, <br>Cardiac, Weight</a>
              <li class="tab-title">
                <a href="#aggression_tab">Aggression &amp; <br>Psychiatric</a>
              </li>
              <li class="tab-title">
                <a href="#cognitive_tab">Cognitive <br>Dysfunction</a>
              </li>
            </ul>
            <div class="tabs-content">
              <section class="content active" id="adj_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>INCIDENCE OF ADVERSE REACTIONS <br>IN ADJUNCTIVE THERAPY STUDIES</h1>
                  </div>
                </figure>
                <div data-tabbed="adj_landing" class="tabbed-content active">
                  <h3>Most common treatment-emergent adverse reactions</h3>
                  <h4>% INCIDENCE OF MOST COMMON* TREATMENT-EMERGENT ADVERSE REACTIONS IN CONTROLLED EPILEPSY POPULATION OR IN PATIENTS WHO INITIATED WITH APTIOM 400 <span class="lowercase">mg</span> WITHOUT CONCOMITANT CARBAMAZEPINE<sup>1,2</sup></h4>
                  <ul class="row collapse" data-tap-to-enlarge="multiple">
                    <li class="relative column">
                      <img alt="" src="img/column-headers_left.png" width="310">
                      <a class="th absolute" rel="adj_left-800" data-group="800">
                        <img alt="" src="img/column-content_left_800.png" width="310">
                      </a>
                      <a class="th absolute" rel="adj_left-1200" data-group="1200">
                        <img alt="" src="img/column-content_left_1200.png">
                      </a>
                    </li>
                    <li class="relative column end">
                      <img alt="" src="img/column-headers_right.png" width="248">
                      <a class="th absolute" rel="adj_right-800" data-group="800">
                        <img alt="" src="img/column-content_right_800.png">
                      </a>
                      <a class="th absolute" rel="adj_right-1200" data-group="1200">
                        <img alt="" src="img/column-content_right_1200.png">
                      </a>
                    </li>
                  </ul>
                  <a class="icon_zoom" href="#adj_incidence_both_sides" data-reveal-id="modal-adj_incidence_both_sides">
                    <img src="../shared/img/icon_zoom.svg" alt="">
                  </a>
                  <aside class="absolute">
                    <p class="undent">*Occurring in &ge;4% of APTIOM patients and <br>&ge;2% greater than placebo.</p>
                    <p class="undent">&dagger;Includes all APTIOM dose initiation groups and concomitant AEDs in placebo-controlled adjunctive epilepsy studies.</p>
                    <button class="button secondary radius expand" data-reveal-id="modal-discontinuations">Adverse Reactions Leading to Discontinuation</button>
                  </aside>
                  <ul class="disc">
                    <li>Some adverse reactions occur more frequently when patients take APTIOM adjunctively with <br>carbamazepine&sup1;</li>
                    <li>Dosage modifications of both APTIOM and carbamazepine and APTIOM and phenytoin should be <br>considered if these drugs are used concomitantly&sup1;</li>
                  </ul>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#400mg_initiation" data-tabbed-id="400mg_initiation">400-<span class="lowercase">mg</span> INITIATION&nbsp;<img class="right" alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <div data-tabbed="400mg_initiation" class="tabbed-content">
                  <h3>Incidences of treatment-emergent adverse reactions were lower when initiating APTIOM at 400 mg vs 800 mg—irrespective of maintenance dose&sup2;</h3>
                  <h4>INCIDENCE OF TREATMENT-EMERGENT ADVERSE REACTIONS REPORTED IN &ge;10% OF PATIENTS IN ANY TITRATION GROUP&sup2;</h4>
                  <figure class="chart">
                    <a class="block relative" data-reveal-id="modal-lower_ae_titration">
                      <img alt="" src="img/chart-lower_ae_titration.svg" width="702">
                      <img src="../shared/img/icon_zoom.svg" class="icon_zoom" alt="">
                    </a>
                    <figcaption>
                      <ul class="disc">
                        <li>76% and 69% of patients who completed Studies 3 and 4 and elected to enter the open-label extension <br>phases (N=314 and 325, respectively) completed 1 year of APTIOM therapy&sup2;</li>
                      </ul>
                    </figcaption>
                  </figure>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#adj_landing" data-tabbed-id="adj_landing" rel="landing" role="back"><img class="right" alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <aside data-isi-link></aside>
              </section>
              <section class="content" id="mono_tab">
                <div data-tabbed="mono_landing" class="tabbed-content active">
                  <figure class="panel callout" data-bg>
                    <div>
                      <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>Study Design and Common adverse REACTIONS IN MONOTHERAPY STUDIES</h1>
                    </div>
                  </figure> 
                  <h3>Adverse reactions were reported throughout the 18-week dose-blinded <br>treatment period: 2-week APTIOM titration, 6-week AED withdrawal, <br>and 10-week monotherapy&nbsp;phases<sup>2</sup></h3>
                  <h4>APTIOM MONOTHERAPY STUDY DESIGN<sup>2</sup></h4>
                  <figure class="chart relative">
                    <div class="absolute">
                      <a data-highlight class="block">
                        <img alt="" src="img/chart_mg-mono_landing_8wk.png" height="139">
                      </a>
                      <a data-highlight class="label no-arrows">8-week <br>baseline</a>
                    </div>
                    <div class="absolute">
                      <a data-highlight="2wk" class="block">
                        <img alt="" src="img/chart_mg-mono_landing_2wk.png" height="139">
                        <svg class="absolute svg-rule_blue" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 1029.1 98.7" enable-background="new 0 0 1029.1 98.7" xml:space="preserve">
                          <polyline id="rule_blue" fill="none" stroke="#201646" stroke-width="4.1648" stroke-miterlimit="10" points="0,96.6 95.3,96.6 
                          95.3,57.1 190.4,57.1 190.4,2.1 1029.1,2.1 "/>
                        </svg>
                        <svg class="absolute svg-rule_gold" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 1029.1 98.7" enable-background="new 0 0 1029.1 98.7" xml:space="preserve">
                          <polyline id="rule_gold" fill="none" stroke="#F38B00" stroke-width="4.1648" stroke-miterlimit="10" points="0,96.6 95.3,96.6 
                          95.3,57.1 190.4,57.1 190.4,2.1 1029.1,2.1 "/>
                        </svg>
                      </a>
                      <a data-highlight="2wk" class="label">2-week <br>titration</a>
                    </div>
                    <div class="absolute" class="block">
                      <a data-highlight="6wk" class="block">
                        <img alt="" src="img/chart_mg-mono_landing_6wk.png" height="139">
                        <svg class="absolute svg-rule_blue" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 1029.1 98.7" enable-background="new 0 0 1029.1 98.7" xml:space="preserve">
                          <polyline id="rule_blue" fill="none" stroke="#201646" stroke-width="4.1648" stroke-miterlimit="10" points="0,96.6 95.3,96.6 
                          95.3,57.1 190.4,57.1 190.4,2.1 1029.1,2.1 "/>
                        </svg>
                        <svg class="absolute svg-rule_gold" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 1029.1 98.7" enable-background="new 0 0 1029.1 98.7" xml:space="preserve">
                          <polyline id="rule_gold" fill="none" stroke="#F38B00" stroke-width="4.1648" stroke-miterlimit="10" points="0,96.6 95.3,96.6 
                          95.3,57.1 190.4,57.1 190.4,2.1 1029.1,2.1 "/>
                        </svg>
                      </a>
                      <a data-highlight="6wk" class="label">6-week <br>AED withdrawal</a>
                    </div>
                    <div class="absolute">
                      <a data-highlight="10wk" class="block">
                        <img alt="" src="img/chart_mg-mono_landing_10wk.png" height="139">
                        <svg class="absolute svg-rule_blue" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 1029.1 98.7" enable-background="new 0 0 1029.1 98.7" xml:space="preserve">
                          <polyline id="rule_blue" fill="none" stroke="#201646" stroke-width="4.1648" stroke-miterlimit="10" points="0,96.6 95.3,96.6 
                          95.3,57.1 190.4,57.1 190.4,2.1 1029.1,2.1 "/>
                        </svg>
                        <svg class="absolute svg-rule_gold" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 1029.1 98.7" enable-background="new 0 0 1029.1 98.7" xml:space="preserve">
                          <polyline id="rule_gold" fill="none" stroke="#F38B00" stroke-width="4.1648" stroke-miterlimit="10" points="0,96.6 95.3,96.6 
                          95.3,57.1 190.4,57.1 190.4,2.1 1029.1,2.1 "/>
                        </svg>
                      </a>
                      <a data-highlight="10wk" class="label">10-week <br>monotherapy phase</a>
                    </div>
                    <svg class="absolute" version="1.1" id="svg-rule_blue" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 1029.1 98.7" enable-background="new 0 0 1029.1 98.7" xml:space="preserve">
                      <polyline id="rule_blue" fill="none" stroke="#201646" stroke-width="4.1648" stroke-miterlimit="10" points="0,96.6 95.3,96.6 
                      95.3,57.1 190.4,57.1 190.4,2.1 1029.1,2.1 "/>
                    </svg>
                    <svg class="absolute" version="1.1" id="svg-rule_gold" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 1029.1 98.7" enable-background="new 0 0 1029.1 98.7" xml:space="preserve">
                      <polyline id="rule_gold" fill="none" stroke="#F38B00" stroke-width="4.1648" stroke-miterlimit="10" points="0,96.6 95.3,96.6 
                      95.3,57.1 190.4,57.1 190.4,2.1 1029.1,2.1 "/>
                    </svg>
                    <a class="block absolute disabled" data-replay-id="modal-adj_results">
                      <img src="../shared/img/icon_replay.svg" class="icon_replay" alt="">
                    </a>
                    <figcaption>
                      <ul role="labels">
                        <li rel="2wk">
                          <img alt="600 mg 400 mg" src="img/chart_labels-2wk.svg" width="77">
                        </li>
                        <li rel="10wk">
                          <img alt="1600 mg 1200 mg" src="img/chart_labels-10wk.svg" width="33">
                        </li>
                      </ul>
                    </figcaption>
                  </figure>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#mono_reaction" data-tabbed-id="mono_reaction">Adverse Reactions&nbsp;<img class="right" alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <div data-tabbed="mono_reaction" class="tabbed-content">
                  <figure class="panel callout" data-bg>
                    <div>
                      <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>Common adverse REACTIONS <br>IN MONOTHERAPY STUDIES</h1>
                    </div>
                  </figure> 
                  <h3>Treatment-emergent adverse reactions were consistent with those observed and attributed to APTIOM in the adjunctive placebo-controlled studies&sup1;</h3>
                  <h4>% INCIDENCE OF MOST COMMON TREATMENT-EMERGENT ADVERSE REACTIONS (&ge;5% OF PATIENTS) THROUGHOUT THE <br>18-WEEK DOSE-BLINDED MONOTHERAPY TREATMENT PERIOD AND THE 10-WEEK MONOTHERAPY PHASE<sup>2</sup></h4>
                  <ul class="row collapse" data-tap-to-enlarge data-chart-key="img/column-mono_exit-key.svg">
                    <li class="relative column">
                      <a class="th absolute" rel="mono_left">
                        <img alt="" src="img/column-mono_exit-left.svg" width="362">
                      </a>
                    </li>
                    <li class="relative column end">
                      <a class="th absolute" rel="mono_right">
                      <img alt="" src="img/column-mono_exit-right.svg" width="247">
                      </a>
                    </li>
                  </ul>
                  <a class="icon_zoom" href="#mono_incidence_both_sides" data-reveal-id="modal-mono_incidence_both_sides">
                    <img src="../shared/img/icon_zoom.svg" alt="">
                  </a>
                  <div class="row">
                    <div class="left">
                      <p class="undent">*Defined as 2 weeks' APTIOM titration + 6 weeks' baseline AED withdrawal + 10 weeks' APTIOM monotherapy.</p>
                    </div>
                    <div class="lt-blue columns">
                      <p class="blue">These monotherapy studies did not include a placebo-control group; therefore, causality could not be established&sup1;</p>
                    </div>
                  </div>
                  <aside class="absolute">
                    <ul class="disc">
                      <li>In adjunctive therapy studies, the most frequently reported adverse reactions (&ge;4% and &ge;2% greater than placebo) in patients receiving APTIOM at doses of 800 mg or 1200 mg or placebo, respectively, were dizziness (20%, 28%, 9%), somnolence (11%, 18%, 8%), nausea (10%, 16%, 5%), headache (13%, 15%, 9%), diplopia (9%, 11%, 2%), vomiting (6%, 10%, 3%), fatigue (4%, 7%, 4%), vertigo (2%, 6%, &lt;1%), ataxia (4%, 6%, 2%), blurred vision (6%, 5%, 1%), and tremor (2%, 4%, 1%)&sup1;</li>
                    </ul>
                  </aside>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#mono_landing" data-tabbed-id="mono_landing" rel="landing" role="back"><img alt="" src="../shared/img/caret.svg"></button>
                    <button class="button tabbed two-line" href="#mono_reaction_more" data-tabbed-id="mono_reaction_more">Additional <br>Information&nbsp;<img class="right" alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <div data-tabbed="mono_reaction_more" class="tabbed-content">
                  <figure class="panel callout" data-bg>
                    <div>
                      <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>Common adverse REACTIONS <br>IN MONOTHERAPY STUDIES</h1>
                    </div>
                  </figure> 
                  <h3>Treatment-emergent adverse reactions were consistent with those observed and attributed to APTIOM in the adjunctive placebo-controlled studies&sup1;</h3>
                  <ul class="disc">
                    <li>Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED withdrawal phase and monotherapy phase compared with the titration phase&sup1;</li>
                    <li>Use of carbamazepine, lamotrigine, levetiracetam, or valproic acid did not predict the occurrence of any common treatment-related adverse reaction&sup2;</li>
                    <li>In adjunctive therapy studies, the most frequently reported adverse reactions (&ge;4% and &ge;2% greater than <br>placebo) in patients receiving APTIOM at doses of 800 mg or 1200 mg or placebo, respectively, were <br>dizziness (20%, 28%, 9%), somnolence (11%, 18%, 8%), nausea (10%, 16%, 5%), headache (13%, 15%, 9%), <br>diplopia (9%, 11%, 2%), vomiting (6%, 10%, 3%), fatigue (4%, 7%, 4%), vertigo (2%, 6%, &lt;1%), ataxia (4%, 6%, 2%), <br>blurred vision (6%, 5%, 1%), and tremor (2%, 4%, 1%)&sup1;</li>
                  </ul>
                  <div class="lt-blue columns">
                    <p class="blue">These monotherapy studies did not include a placebo-control group; therefore, causality could not be&nbsp;established&sup1;</p>
                  </div>
                  <nav class="tabbed-nav">
                    <button class="button tabbed" href="#mono_reaction" data-tabbed-id="mono_reaction" rel="reaction_more" role="back"><img alt="" src="../shared/img/caret.svg"></button>
                  </nav>
                </div>
                <aside data-isi-link></aside>
              </section>
              <section class="content" id="hypnatremia_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>ADVERSE REACTIONS AND OTHER <br>CONSIDERATIONS</h1>
                  </div>
                </figure>
                <h3>% incidence of hyponatremia (sodium &lt;125 mEq/L) in APTIOM clinical studies&sup1;</h3>
                <figure class="chart">
                  <img alt="" src="img/chart-incidence_hyponatremia.svg">
                  <figcaption>
                    <ul class="disc">
                      <li>Hyponatremia was also observed in monotherapy studies&sup1;</li>
                    </ul>
                  </figcaption>
                </figure>
                <h3>Other considerations</h3>
                <h5>No significant effect on cardiac conduction</h5>
                <ul class="disc">
                  <li>No significant effect on QTc interval was detected in a dedicated QTc study; routine ECG monitoring is not required<sup>1,2</sup></li>
                </ul>
                <h5>Effect on weight vs placebo in adjunctive epilepsy studies</h5>
                <ul class="disc">
                  <li>Mean changes in weight in controlled adjunctive epilepsy studies were 0.3 kg, 0.3 kg, and 0.3 kg for placebo, APTIOM 800 mg, and APTIOM 1200 mg, respectively.&sup2; However, given variability in patients who either lost or gained weight, no definitive conclusions regarding weight changes and APTIOM use can be made</li>
                </ul>
                <aside data-isi-link></aside>
              </section>
              <section class="content" id="aggression_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>AGGRESSION-RELATED AND<br />PSYCHIATRIC ADVERSE REACTIONS</h1>
                  </div>
                </figure>
                <h3>Incidences of most common aggression-related and psychiatric adverse reactions <br>with APTIOM vs placebo in adjunctive epilepsy studies&sup2;</h3>
                <figure class="chart">
                  <a class="block relative" data-reveal-id="modal-common_psychiatric">
                    <img alt="" src="img/chart-common_psychiatric.svg" width="702">
                    <img src="../shared/img/icon_zoom.svg" class="icon_zoom" alt="">
                  </a>
                  <figcaption>
                    <p>*Defined as events occurring in the Standardised MedDRA Queries (SMQ) of hostility/aggression.</p>
                    <p>&dagger;Defined as events occurring in the System Organization Class (SOC) of psychiatric disorders.</p>
                    <p>&Dagger;Includes APTIOM 400 mg, 800 mg, and 1200 mg.</p>
                  </figcaption>
                </figure>
                <ul class="disc">
                  <li>Incidences of aggression and agitation with APTIOM were comparable to placebo in adjunctive epilepsy studies&sup2;</li>
                </ul>
                <aside data-isi-link></aside>
              </section>
              <section class="content" id="cognitive_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>COGNITIVE DYSFUNCTION–RELATED <br>ADVERSE EVENTS IN ADJUNCTIVE EPILEPSY STUDIES</h1>
                  </div>
                </figure>
                <h3>Most common cognitive dysfunction–related adverse events</h3>
                <ul class="disc">
                  <li>The incidences of individual cognitive dysfunction–related adverse events were &le;1.7% with  APTIOM 800-mg and 1200-mg maintenance doses&sup2;</li>
                  <li>The most common cognitive dysfunction–related adverse events (occurring in &ge;1% of patients) with placebo, APTIOM 800 mg, and APTIOM 1200 mg, respectively, in adjunctive epilepsy studies were: irritability (0.5%, 1.2%, 0.7%), memory impairment (0.2%, 1.0%, 1.7%), disturbance in attention (0.5%, 0.7%, 1.5%), amnesia (0.2%, 1.0%, 0.7%), apathy (0%, 0%, 1.2%), and aphasia (0%, 0.2%, 1.2%)&sup2;</li>
                  <li>Cognitive dysfunction events were also observed in monotherapy studies&sup1;</li>
                </ul>
                <h3>Dose-dependent increases in cognitive dysfunction&ndash;related events</h3>
                <h4>% INCIDENCES OF DOSE-DEPENDENT COGNITIVE DYSFUNCTION–RELATED EVENTS IN <br>APTIOM ADJUNCTIVE EPILEPSY STUDIES<sup>1,2</sup></h4>
                <figure class="chart">
                  <a class="block relative" data-reveal-id="modal-dose_dependence">
                    <img alt="" src="img/chart-dose_dependence.svg" width="570">
                    <img src="../shared/img/icon_zoom.svg" class="icon_zoom" alt="">
                  </a>
                  <figcaption>
                    <ul class="disc">
                      <li>Dose-dependent cognitive dysfunction–related events were reported in 1% of placebo patients, 4% of patients on <br>APTIOM 800 mg, and 7% of patients on APTIOM 1200 mg&sup1;</li>
                      <li>Cognitive dysfunction–related events were serious in 0.2% of APTIOM-treated patients (and 0.2% of placebo patients) <br>and led to discontinuation in 1% of APTIOM-treated patients (and 0.5% of placebo-treated patients)&sup1;</li>
                    </ul>
                  </figcaption>
                </figure>
                <aside data-isi-link></aside>
              </section>
            </div>
          </article>
          <article class="row portrait"></article>
        </section>
        <aside id="sidebar" class="columns"></aside>
      </div>
    </main>
		<footer id="footer-menu" class="footer-menu landscape"></footer>
    <div id="modals"></div>
    <div id="modal-adj_incidence_both_sides" data-reveal class="reveal-modal full" aria-labelledby="modal-adj_incidence_both_sides-title" aria-hidden="true" role="dialog">
      <h3 id="modal-adj_incidence_both_sides-title" class="blue">% INCIDENCE OF MOST COMMON* TREATMENT-EMERGENT ADVERSE REACTIONS IN CONTROLLED EPILEPSY POPULATION OR IN PATIENTS WHO INITIATED WITH APTIOM 400 <span class="lowercase">mg</span> WITHOUT CONCOMITANT CARBAMAZEPINE&sup1;<sup>,</sup>&sup2;</h3>
      <figure>
        <img alt="" src="img/chart-adj_incidence_both_sides.png" width="100%">
        <figcaption>
          <ul class="asterisk">
            <li>Occurring in &ge;4% of APTIOM patients and &ge;2% greater than placebo.</li>
          </ul>
          <ul class="dagger">
            <li>Includes all APTIOM dose initiation groups and concomitant AEDs in placebo-controlled adjunctive epilepsy studies.</li>
          </ul>
        </figcaption>
      </figure>
      <a class="close-reveal-modal" aria-label="Close">&#215;</a>
    </div>
    <div id="modal-discontinuations" data-reveal class="reveal-modal" aria-labelledby="modal-discontinuations-title" aria-hidden="true" role="dialog">
      <h3 id="modal-discontinuations-title" class="blue">INCIDENCE OF TREATMENT-EMERGENT ADVERSE REACTIONS LEADING TO DISCONTINUATION WAS LOWER WITH INITIATION OF APTIOM 400 <span class="lowercase">mg</span> WITHOUT CONCOMITANT CARBAMAZEPINE&sup1;<sup>,</sup>&sup2;</h3>
      <figure>
        <img alt="" src="img/chart-discontinuations.svg" width="100%">
        <figcaption>
          <p>&Dagger;Includes all APTIOM dose initiation groups and concomitant AEDs in placebo-controlled adjunctive epilepsy studies.</p>
        </figcaption>
      </figure>
      <ul class="disc">
        <li>The adverse reactions that most commonly led to discontinuation (incidence ≥1% in any APTIOM treatment <br>group and greater than placebo) in descending order of frequency were dizziness, nausea, vomiting, ataxia, <br>diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor&sup1;</li>
      </ul>
      <a class="close-reveal-modal" aria-label="Close">&#215;</a>
    </div>
    <div id="modal-lower_ae_titration" data-reveal class="reveal-modal full" aria-labelledby="modal-lower_ae_titration-title" aria-hidden="true" role="dialog">
      <h3 id="modal-lower_ae_titration-title" class="blue">INCIDENCE OF TREATMENT-EMERGENT ADVERSE REACTIONS REPORTED IN &ge;10% OF PATIENTS IN <br>ANY TITRATION GROUP&sup2;</h3>
      <figure>
        <img alt="" src="img/chart-lower_ae_titration.svg" width="100%">
      </figure>
      <a class="close-reveal-modal" aria-label="Close">&#215;</a>
    </div>
    <div id="modal-mono_incidence_both_sides" data-reveal class="reveal-modal full" aria-labelledby="modal-mono_incidence_both_sides-title" aria-hidden="true" role="dialog">
      <h3 id="modal-mono_incidence_both_sides-title" class="blue">% INCIDENCE OF MOST COMMON TREATMENT-EMERGENT ADVERSE REACTIONS (&ge;5% OF PATIENTS) THROUGHOUT THE 18-WEEK DOSE-BLINDED MONOTHERAPY TREATMENT PERIOD AND THE 10-WEEK MONOTHERAPY PHASE&sup2;</h3>
      <figure>
        <img alt="" src="img/chart-mono_incidence_both_sides.svg" width="100%">
        <figcaption>
          <div class="left">
            <p>*Defined as 2 weeks' APTIOM titration + 6 weeks' baseline AED withdrawal + 10 weeks' APTIOM monotherapy.</p>
          </div>
          <div class="lt-blue columns">
            <p class="blue">These monotherapy studies did not include a placebo-control group; therefore, causality could not be established&sup1;</p>
          </div>
        </figcaption>
      </figure>
      <a class="close-reveal-modal" aria-label="Close">&#215;</a>
    </div>
    <div id="modal-common_psychiatric" data-reveal class="reveal-modal full" aria-hidden="true" role="dialog">
      <figure>
        <img alt="" src="img/chart-common_psychiatric.svg" width="100%">
        <figcaption>
          <p>*Defined as events occurring in the Standardised MedDRA Queries (SMQ) of hostility/aggression.</p>
          <p>&dagger;Defined as events occurring in the System Organization Class (SOC) of psychiatric disorders.</p>
          <p>&Dagger;Includes APTIOM 400 mg, 800 mg, and 1200 mg.</p>
        </figcaption>
      </figure>
      <a class="close-reveal-modal" aria-label="Close">&#215;</a>
    </div>
    <div id="modal-dose_dependence" data-reveal class="reveal-modal full" aria-hidden="true" role="dialog">
      <h3 id="modal-mono_incidence_both_sides-title" class="blue">% INCIDENCES OF DOSE-DEPENDENT COGNITIVE DYSFUNCTION–RELATED EVENTS IN <br>APTIOM ADJUNCTIVE EPILEPSY STUDIES&sup1;<sup>,</sup>&sup2;</h3>
      <figure>
        <img alt="" src="img/chart-dose_dependence.svg" width="100%">
      </figure>
      <a class="close-reveal-modal" aria-label="Close">&#215;</a>
    </div>
    <script type="text/javascript" src="../shared/js/vendor/jquery.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/veeva-library-4.2.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/ivaHelper-1.0.1.js"></script>
    <script type="text/javascript" src="../shared/js/foundation.min.js"></script>
    <script type="text/javascript" src="../shared/js/foundation/foundation.reveal.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/jquery.touchSwipe.min.js"></script>
		<script type="text/javascript" src="../shared/js/vendor/iscroll.js"></script>
    <script type="text/javascript" src="../shared/js/global.js"></script>
    <script type="text/javascript" src="js/slide.js"></script>
  </body>
</html>